2025
PP01.20 Predictive Utility of Circulating Tumor DNA in First- Line Osimertinib Therapy for EGFR-Mutant Metastatic Lung Adenocarcinoma
Paredes R, Goto T, Litchman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Smith C, Rohs N, Rolfo C. PP01.20 Predictive Utility of Circulating Tumor DNA in First- Line Osimertinib Therapy for EGFR-Mutant Metastatic Lung Adenocarcinoma. Journal Of Thoracic Oncology 2025, 20: s9-s10. DOI: 10.1016/j.jtho.2025.03.025.Peer-Reviewed Original ResearchMetastatic lung adenocarcinomaCirculating tumor DNAOsimertinib therapyTumor DNALung adenocarcinomaAdenocarcinoma
2022
Synchronous glioblastoma and brain metastases: illustrative case
Shahsavari N, Ahmad M, Sekar V, Meola A, Hancock SL, Chang SD, Chiang VL. Synchronous glioblastoma and brain metastases: illustrative case. Journal Of Neurosurgery Case Lessons 2022, 3: case21714. PMID: 36273867, PMCID: PMC9379681, DOI: 10.3171/case21714.Peer-Reviewed Original ResearchBrain metastasesMultiple brain metastasesRadiosurgical treatmentSignificant perilesional edemaSimilar radiological featuresMetastatic lung adenocarcinomaRight temporal lobeStereotactic radiosurgical treatmentMaintenance nivolumabRadiological featuresMidline shiftPerilesional edemaTreatment courseTissue confirmationLung adenocarcinomaStereotactic radiosurgeryTemporal lobeMetastasisIllustrative caseIncorrect diagnosisRadiological surveillanceSynchronous presenceIDH-wildtypeGlioblastomaLesionsTargeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma
Mack P, Klein M, Ayers K, Zhou X, Guin S, Fink M, Rossi M, AI-Kateb H, O’Connell T, Hantash F, Oh W, Newman S, Schadt E, Chen R, Hirsch F. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. The Oncologist 2022, 27: 476-486. PMID: 35298662, PMCID: PMC9177106, DOI: 10.1093/oncolo/oyac035.Peer-Reviewed Original ResearchConceptsStage IV patientsActionable driver mutationsLung adenocarcinomaDriver mutationsIV patientsDiagnosis of adenocarcinomaMetastatic lung adenocarcinomaNext-generation sequencing panelEGFR-mutant tumorsTargeted Next-Generation SequencingHigh rateAssociated therapyNTRK1-3Never smokersMost patientsMultivariable analysisSmoking statusFemale sexSmokersKRAS G12CPatientsAdenocarcinomaDriver alterationsSequencing panelMutation group
2014
Metastatic squamous cell carcinoma presenting as an erythematous nodule in a man with lung adenocarcinoma.
Korta D, Lewin J, Meehan S, Ramachandran S. Metastatic squamous cell carcinoma presenting as an erythematous nodule in a man with lung adenocarcinoma. Journal Of Drugs In Dermatology 2014, 13: 1277-9. PMID: 25607566.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLung cancerSkin lesionsSkin metastasesPrimary malignancyCell carcinomaLung adenocarcinomaMetastatic squamous cell carcinomaSecond primary lung cancerSquamous cell carcinoma presentingNovel chemotherapeutic regimenOccult internal malignancyRetroperitoneal lymph nodesSecond primary malignanciesPatient's skin lesionsPoor prognostic signPrimary lung cancerMetastatic lung adenocarcinomaMetastatic skin lesionsCutaneous metastasesVisceral cancerCarcinoma presentingChemotherapeutic regimenVisceral malignancyInternal malignancy
2013
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma
Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathology 2013, 121: 500-507. PMID: 23495083, DOI: 10.1002/cncy.21288.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseBiomarkers, TumorBone NeoplasmsCytodiagnosisDNA, NeoplasmErbB ReceptorsFeasibility StudiesFemaleGene RearrangementHumansIn Situ Hybridization, FluorescenceLiver NeoplasmsLung NeoplasmsMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesSoft Tissue NeoplasmsYoung AdultConceptsALK gene rearrangementMetastatic lung adenocarcinomaEGFR mutationsKRAS mutationsMetastatic tumorsEpidermal growth factor receptorLung adenocarcinomaCytological specimensGene rearrangementsMolecular testsMolecular alterationsKirsten rat sarcoma viral oncogene homolog (KRAS) mutationsALK gene rearrangement analysisAnaplastic lymphoma kinase (ALK) gene rearrangementEGFR T790M mutationRat sarcoma viral oncogene homolog mutationsCases of lungT790M mutationImportant therapeutic implicationsFine needle aspiratesGene rearrangement analysisCell block materialGrowth factor receptorRecurrent lungRecurrent adenocarcinoma
2012
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
Sangodkar J, Dhawan N, Melville H, Singh V, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, DiFeo A, Narla G. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. Journal Of Clinical Investigation 2012, 122: 2637-2651. PMID: 22653055, PMCID: PMC3386822, DOI: 10.1172/jci62058.Peer-Reviewed Original ResearchMeSH KeywordsActive Transport, Cell NucleusAdenocarcinomaAdenocarcinoma of LungAnimalsAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmDrug SynergismEnzyme ActivationErbB ReceptorsErlotinib HydrochlorideFemaleForkhead Box Protein O1Forkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansKruppel-Like Factor 6Kruppel-Like Transcription FactorsLung NeoplasmsMiceMice, Inbred BALB CMice, NudeMutationProto-Oncogene ProteinsProto-Oncogene Proteins c-aktQuinazolinesReal-Time Polymerase Chain ReactionSignal TransductionTranscription, GeneticTrifluoperazineTumor BurdenXenograft Model Antitumor AssaysConceptsAnti-EGFR-based therapyEGFR SignalingKruppel-like factor 6Lung adenocarcinomaForkhead box O1Xenograft models of lung adenocarcinomaModel of lung adenocarcinomaMetastatic lung adenocarcinomaTreat advanced cancersMolecular drivers of disease progressionDrivers of disease progressionOncogenic EGFR signalingActivation of Akt signalingFoxO1 nuclear exportTreating resistant diseaseIn vivo modelsCell culturesErlotinib resistanceResistant diseaseTreatment responseMolecular therapiesXenograft modelFDA-approved drugsDisease progressionEGFR activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply